This MTAP deletion-induced vulnerability is extend to the MAT2A, the upstream enzymes of PRMT5, and three kinds of MAT2A inhibitor (AG-270, S-095033, and IDE-397) are currently in the phase I clinical trials for the therapy of MTAP-deleted cancers (141). Here, PRMT5 is linked to cancer.